Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis.
Kazuki OhyaMichio ImamuraYuji TeraokaKei MorioHatsue FujinoTakashi NakaharaAtsushi OnoEisuke MurakamiTomokazu KawaokaDaiki MikiMasataka TsugeAkira HiramatsuHiroshi AikataC Nelson HayesNami MoriShintaro TakakiKeiji TsujiYasuyuki AisakaTomokazu IshitobiYoshio KatamuraHideaki KodamaYoshitaka NabeshimaKeiichi MasakiYohji HondaTakashi MoriyaHirotaka KohnoHiroshi KohnoKazuaki ChayamaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2020)
The effect of SOF/VEL therapy is lower for patients with Child C. Improvement of hepatic function is expected after viral eradication with SOF/VEL therapy in patients with decompensated cirrhosis.